Tarsons swings to ₹1.4 Cr consolidated loss in Q1 FY27 despite 20.7% YoY revenue growth

Tarsons Products' consolidated result for the quarter ended June 30, 2026 shows revenue of ₹110.24 Cr, up 20.7% YoY from ₹91.36 Cr but down 8.8% QoQ from a seasonally stronger ₹120.93 Cr in Q4 FY26. Despite the topline growth, the group swung to a net loss of ₹1.44 Cr (EPS ₹(0.27)) against a profit of ₹1.78 Cr a year ago and ₹4.18 Cr last quarter. Neither the current nor year-ago quarter carried exceptional items, and last quarter's ₹0.22 Cr labour-code exceptional cost is also absent here, so this is a purely operational swing, not a one-off.

Cost of materials, traded goods and inventory movements rose to 35.1% of revenue from 32.1% a year ago, consistent with management's Q4 FY26 concall warning that raw-material price increases would pressure Q1 FY27 margins toward Q4 FY26 levels. Operating margin came in around 23.6%, however — below both the year-ago 27.0% and the ~28.5% level management pointed to, a miss against its own framing. The bigger drag sat below the operating line: depreciation jumped 42% YoY to ₹27.02 Cr (24.5% of revenue vs 20.8% a year ago) as capex commissioning proceeds, and finance costs rose 23.5% YoY to ₹6.27 Cr. Together, D&A and finance costs absorbed the operating profit and pushed the group to a ₹1.32 Cr pre-tax loss and, after a ₹0.12 Cr tax charge, a ₹1.44 Cr net loss.

The stock went into the print at ₹313.5, up 3.4% over the past month of trading.

Standalone (India-only) results diverge sharply: standalone PAT was a profit of ₹0.68 Cr (EPS ₹0.13) on revenue of ₹86.15 Cr, indicating the consolidated loss originates from the overseas subsidiaries (Tarsons Life Science Pte Ltd, Singapore, and its German units) and consolidated-level D&A/finance allocations rather than the core India business. The auditor's review report notes two smaller step-down subsidiaries, not yet reviewed by their own auditors, posted a combined net loss of roughly ₹0.18 Cr this quarter, which management calls immaterial to the Group. No press release or MD&A accompanied the filing beyond the SEBI outcome letter and financial statements. A web search found no quarter-specific street estimate for Q1 FY27 revenue or PAT; general analyst commentary (citing JM Financial and Kotak Securities targets) points to a full-year FY27 PAT growth expectation of 15-20%, a bar this quarter's swing to a consolidated loss does not support on its own, though one quarter does not decide the year. The quarter also saw an HR head resignation, unrelated to the financial print.